Sheila Breidinger
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV Research and Treatment, Biosimilars and Bioanalytical Methods, HIV/AIDS Research and Interventions, Pharmacogenetics and Drug Metabolism
Most-Cited Works
- → Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms(2009)90 cited
- → Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects(2008)87 cited
- → Effects of Omeprazole on Plasma Levels of Raltegravir(2009)86 cited
- → Extractability-mediated stability bias and hematocrit impact: High extraction recovery is critical to feasibility of volumetric adsorptive microsampling (VAMS) in regulated bioanalysis(2018)75 cited
- → Lack of a Significant Drug Interaction between Raltegravir and Tenofovir(2008)72 cited
- → Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir(2008)65 cited
- → Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1(2010)57 cited
- → Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics(2010)54 cited
- → Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics(2009)44 cited
- → Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval(2008)41 cited